Drug intelligence / Profile preview

Rabifel

Development stage: Unknown
Lead developer: Indian Immunologicals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

Rabifel is an inactivated rabies vaccine for cats used in veterinary medicine to induce active immunity against rabies virus, thereby preventing rabies in vaccinated animals. It is an immunobiological product containing killed rabies virus antigen formulated with adjuvants; following subcutaneous or intramuscular administration, it stimulates the feline immune system to generate neutralizing antibodies, with protective immunity developing approximately 2–3 weeks after vaccination.[7] The vaccine is intended for prophylactic use in healthy cats, typically as part of routine vaccination schedules in regions where rabies is endemic or under regulatory control.[7]

Brand names: Rabifel
Other names: Rabifel vaccine against feline rabies

Beyond the preview

Go deeper on Rabifel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabifel.

Explore the full profile